Lark Deal Gives Genaissance Base in Europe. Are Euro-Pharmas Hungry Enough for PGx? | GenomeWeb

Genaissance Pharmaceuticals has gotten a taste of Europe, and it wants some more.

When the company acquires Lark Technologies for $20 million in stock later this year, it will obtain a presence on the Continent, a scrappy sales team, and a complementary array of services to blend with its own offerings.

The new European footprint, following on a pair of recent deals with mid-sized European biopharmas, will also buoy Genaissance’s financial outlook for 2003 — if only in pro forma standards.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.